AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
Recruiting
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT06380738
- Locations
- 🇩🇪
Research Site, Wetzlar, Germany
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Phase 3
Recruiting
- Conditions
- Advanced Breast Cancer
- Interventions
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 500
- Registration Number
- NCT06380751
- Locations
- 🇬🇧
Research Site, Taunton, United Kingdom
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Oral AZD0233 Compared With Placebo in Healthy Adult Participants.
- First Posted Date
- 2024-04-24
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 88
- Registration Number
- NCT06381466
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
Recruiting
- Conditions
- Lung NeoplasmsCarcinoma, BronchogenicRespiratory Tract DiseasesBronchial NeoplasmsRespiratory Tract NeoplasmsCarcinoma, Non-Small-Cell LungThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung Diseases
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 700
- Registration Number
- NCT06376084
- Locations
- 🇨🇳
Research Site, Shanghai, China
Lung Cancer Screening Program Using Low-dose Tomography and Metabolomic Evaluation in a Public Service.
Recruiting
- Conditions
- Lung Cancer
- First Posted Date
- 2024-04-19
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT06376097
- Locations
- 🇧🇷
Hospital das Clínicas da Faculdade de Medicina de Botucatu (HCFMB), Botucatu, São Paulo, Brazil
PRospectIve ObseRvatIonal mulTicenter Study of Patients With Arterial hYpertension and CKD in the Population of Russia
Recruiting
- Conditions
- Arterial Hypertension, Chronic Kidney Disease
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10000
- Registration Number
- NCT06372431
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
A Study to Investigate the Safety and Pharmacokinetics of AZD6793 in Healthy Japanese and Chinese Participants
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 39
- Registration Number
- NCT06368440
- Locations
- 🇺🇸
Research Site, Glendale, California, United States
Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD
Recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT06368427
- Locations
- 🇷🇴
Research Site, Timisoara, Romania
hATTR Polyneuropathy in Russia
Completed
- Conditions
- Hereditary Transthyretin Amyloidosis
- First Posted Date
- 2024-04-15
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06365593
- Locations
- 🇷🇺
Research Site, Saint-Petersburg, Russian Federation
Real-World Treatment Study of Koselugo (Selumetinib)
Recruiting
- Conditions
- Neurofibromatosis 1Neurofibroma, Plexiform
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT06360406
- Locations
- 🇰🇷
Research Site, Yangsan-si, Korea, Republic of
🇰🇷Research Site, Yangsan-si, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath